AUD280.22
0.30% today
Australia, Nov 26, 06:10 am CET
ISIN
AU000000CSL8
Symbol
CSL
Sector
Industry

CSL Stock price

AUD280.22
-11.78 4.03% 1M
+1.61 0.58% 6M
-2.56 0.91% YTD
+27.40 10.84% 1Y
-20.14 6.71% 3Y
+16.32 6.18% 5Y
+209.31 295.15% 10Y
Australia, Closing price Tue, Nov 26 2024
-0.85 0.30%
ISIN
AU000000CSL8
Symbol
CSL
Sector
Industry

Key metrics

Market capitalization AUD136.10b
Enterprise Value AUD154.91b
P/E (TTM) P/E ratio 33.60
EV/FCF (TTM) EV/FCF 53.24
EV/Sales (TTM) EV/Sales 6.91
P/S ratio (TTM) P/S ratio 6.07
P/B ratio (TTM) P/B ratio 5.22
Dividend yield 1.42%
Last dividend (FY24) AUD4.00
Revenue growth (TTM) Revenue growth 14.47%
Revenue (TTM) Revenue AUD22.43b
EBIT (operating result TTM) EBIT AUD5.66b
Free Cash Flow (TTM) Free Cash Flow AUD2.91b
EPS (TTM) EPS AUD8.36
P/E forward 29.11
P/S forward 5.63
EV/Sales forward 6.41
Show more

Is CSL a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

CSL Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a CSL forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a CSL forecast:

Buy
86%
Hold
14%

Financial data from CSL

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
22,426 22,426
14% 14%
100%
- Direct Costs 11,506 11,506
14% 14%
51%
10,920 10,920
15% 15%
49%
- Selling and Administrative Expenses 1,648 1,648
19% 19%
7%
- Research and Development Expense 2,182 2,182
19% 19%
10%
7,090 7,090
27% 27%
32%
- Depreciation and Amortization 1,431 1,431
16% 16%
6%
EBIT (Operating Income) EBIT 5,659 5,659
30% 30%
25%
Net Profit 4,039 4,039
21% 21%
18%

In millions AUD.

Don't miss a Thing! We will send you all news about CSL directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Paul McKenzie
Employees 32,000
Founded 1961
Website www.csl.com.au

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today